公司解散和裁员 - 公司计划解散和清算，已获董事会批准并需要股东批准[65] - 公司将进行裁员，预计将产生170万美元的一次性费用[65] 产品开发情况 - 公司的临床阶段产品候选药物包括TRC102和YH001，其中TRC102正在进行临床试验[67,67] - 公司已将产品开发平台授权给Inhibrx公司，获得300万美元的首付费用[71] - 公司与3D Medicines和Alphamab合作开发envafolimab用于治疗肉瘤[72] 费用情况 - 公司的研发费用主要包括第三方费用和内部人员及设施费用[73,74,75] - 公司预计随着envafolimab开发的终止和公司计划解散,研发费用将会降低[75] - 公司预计2024年剩余时间内一般及行政费用将有所下降,主要是由于停止进一步开发envafolimab以及公司计划解散[76] 财务状况 - 2023年6月30日的累计亏损为2.465亿美元,公司预计未来可预见的将继续亏损[86] - 公司于2024年6月30日的现金及现金等价物为6.3百万美元,主要用于支付解散和裁员的相关费用,现有现金不足以满足未来一年内到期的义务[91] 其他收支 - 2024年其他收入主要由短期现金等价物产生的利息收入构成,2023年其他费用主要由2022年12月签订的仲裁融资协议相关的利息构成[77] - 公司预计2024年剩余时间内研发费用和一般及行政费用将随着停止envafolimab的进一步开发和公司计划解散而有所下降[81,84]

SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB:TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.  The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. s ...

SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.  The board of directors appointed Craig R. Jalbert, age 62, as the Company’s CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. ...

The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint of 11% Company will focus on exploring strategic alternatives, that may include a variety of strategic transactions such as a reverse merger, acquisition, sale of all assets, or other strategic transactions leveraging its in-house Product Development Platform of CRO-independent clinical trial execution SAN DI ...

财务数据和关键指标变化 - 研发费用从2023年同期的500万美元下降至2024年第一季度的190万美元,主要是由于2023年终止了ENVASARC试验的D组 [29] - 一般及管理费用从2023年同期的230万美元下降至2024年第一季度的140万美元,主要是由于法律费用的降低 [30] - 净亏损从2023年同期的850万美元下降至2024年第一季度的320万美元 [30] - 2024年3月31日,公司现金、现金等价物和受限现金总计800万美元,较2023年12月31日的860万美元有所下降 [31] 各条业务线数据和关键指标变化 - 公司正在进行ENVASARC关键性试验,预计2024年第三季度报告最终数据 [33] - ENVASARC试验单药ENVA组的客观缓解率为11%(调查者评估)和5.5%(独立中心评估),ENVA单药耐受性良好 [6][7] - 公司计划在ENVASARC试验完成入组并在预期递交生物制品许可申请前,启动ENVA联合阿霉素用于一线治疗的试验,以确定最佳适应症 [11][12][13][14] 各个市场数据和关键指标变化 - 公司获得ENVA在UPS和MFS适应症的快速通道和孤儿药资格认定,这可能加快监管审查 [10] 公司战略和发展方向及行业竞争 - 公司的临床开发策略旨在通过寻求补充生物制品许可申请,为ENVA在一线、辅助和新辅助治疗中广泛惠及患者创造机会 [15] - 公司的产品开发平台(PDP)可以以低于CRO成本但仍高于自身成本的方式为合作伙伴执行临床试验,并通过授权PDP获得非稀释性资本 [18][19][20][21][22][24][25] - 公司正在考虑通过PDP业务开发或融资等方式,在6月30日之前满足纳斯达克的最低市值或股东权益要求 [27] 管理层对经营环境和未来前景的评论 - 公司期望ENVA在一线、辅助和新辅助治疗中为肉瘤患者带来广泛益处,而不仅仅是在难治复发UPS和MFS中获批预期的2亿美元峰值年销售额 [15] - 公司相信其PDP已经建立了良好的信誉,为希望实现无CRO运营并获得更快、更高质量且更低成本的临床试验执行的公司提供了一种有吸引力的解决方案 [25] 问答环节重要的提问和回答 问题1 **Matthew Venezia 提问** 询问公司通过PDP运营临床试验的利润率 [37][38][39] **Charles Theuer 回答** 公司过去运营I-Mab的一项I期试验,总成本不到300万美元,收取900万美元,利润率约为200%。公司可以以每患者10万美元的成本运营肿瘤试验,而CRO报价通常为每患者30万美元 [38][39] 问题2 **Matthew Venezia 提问** 询问公司如何在6月30日之前满足纳斯达克的最低市值或股东权益要求,以及与ENVASARC数据时间线的关系 [40][41][42][43] **Charles Theuer 回答** 公司首选通过PDP业务开发获得收入来满足股东权益要求,如果需要也可能进行融资。ENVASARC最终数据预计在2024年第三季度公布,略晚于6月30日的纳斯达克合规期限 [41][42][43]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36818 TRACON Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 34-2037594 (State or other jurisdiction of (IRS Employer incorporation or ...

Exhibit 99.1 TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update San Diego, CA – May 14, 2024 – TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024. The Company will ho ...

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Charles Theuer - President & Chief Executive Officer Scott Brown - Chief Financial Officer Conference Call Participants Soumit Roy - Jones Research Steve Bersey - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals Fourth Quarter and Year-End 2023 Earnings Conference Call. [Operator Instructions] During today's call, we will be making certai ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36818 TRACON Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 34-2037594 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organ ...

Exhibit 99.1 TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update San Diego, CA – March 5, 2024 – TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 3 ...